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Advances in genome-wide molecular cytogenetics allow identification of novel submicroscopic DNA copy number
alterations (aCNAs) and copy-neutral loss of heterozygosity (cnLOH) resulting in homozygosity for known gene
mutations in myeloid neoplasms. We describe the use of an oligo-SNP array for genomic profiling of aCNA and
cnLOH, together with sequence analysis of recurrently mutated genes, in a patient with myelodysplastic syndrome
(MDS) presenting with normal karyotype and FISH results. Oligo-SNP array analysis revealed a hemizygous deletion
of 896 kb at chromosome 5q31.2, representing the smallest 5q deletion reported to date. The deletion involved
multiple genes, including two tumor suppressor candidate genes (CTNNA1 and HSPA9) that are associated with
MDS/AML. The SNP-array study also detected 3 segments of somatic cnLOH: one involved the entire long arm of
chromosome 4; the second involved the distal half of the long arm of chromosome 7, and the third encompassed
the entire chromosome 22 (UPD 22). Sequence analysis revealed mutations in TET2 (4q), EZH2 (7q), ASXL1
(20q11.21), and RUNX1 (21q22.3). Coincidently, TET2 and EZH2 were located at segments of cnLOH resulting in their
homozygosity. Loss of heterozygosity affecting these two chromosomes and mutations in TET2 and EZH2 are indicative
of a myelodysplastic syndrome with a poor prognosis. Deletion of the tumor suppressor genes CTNNA1 and HSPA9 is
also likely to contribute to a poor prognosis. Furthermore, the original cnLOHs in multiple chromosomes and additional
cnLOH 14q in the follow-up study suggest genetic evolution of the disease and poor prognosis. This study attests to
the fact that some patients with a myelodysplastic syndrome who exhibit a normal karyotype may have underlying
genetic abnormalities detectable by chromosomal microarray and/or targeted mutation analyses.
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Recent advances in genome-wide molecular cytogenetics
allow the identification of novel molecular abnormalities
[1-8]. Emerging data demonstrate that myelodysplastic
syndrome (MDS) exhibits abundant CNAs and cnLOH,
often in the setting of a normal karyotype [9-11]. Loss of* Correspondence: morteza.x.hemmat@questdiagnostics.com
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lution and disease progression [12,13]. Copy-neutral
LOH (cnLOH) arises either via a hemizygous deletion in
one homolog and duplication of the other, or uniparental
disomy (UPD). Both types of somatic LOH have been ob-
served in studies of various cancer types and may explain
some of the mechanisms by which tumor suppressor
genes (TSGs) are inactivated or activating mutations in
oncogenes are duplicated. Acquired UPD (aUPD) is now
understood to be common in oncogenesis and appears toal Ltd. This is an Open Access article distributed under the terms of the Creative
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mutated genes [14-24]. Thus, it is important to know the
regions of cnLOH to determine new regions containing
potential mutational targets affecting disease pathogenesis
and treatment outcome [25,26].
Application of SNP-array technology has led to the iden-
tification of recurrent regions of cnLOH in a majority of
the chromosomes [4,13,25,27-30] and recurrent pathogenic
mutations. These findings have greatly advanced our under-
standing of the molecular mechanisms of cancer evolution
and have led to the development of therapeutics and diag-
nostic tests. In this respect, mutation analysis helps further
stratify neoplasms and their treatment outcome [31-34].
In this study, we used SNP array-based genomic
profiling to detect acquired copy number alterations
(aCNA) and cnLOHs, together with sequence analysis
of genes commonly mutated in MDS, in a patient with
normal chromosome and MDS FISH (fluorescence in
situ hybridization) panel results.
Clinical presentation
Morphologic and immunophenotypic findings
An 88-year-old woman presented with leukocytosis
(16.2×109/L) including minimal monocytosis (1.0×109/L),
mild anemia (HGB 105 g/L), and moderate thrombocytopenia
(79×109/L). Bone marrow morphologic and flow cytometric
examinations revealed hypercellular bone marrow with
granulocytic predominance with left-shifted and unusualFigure 1 Morphologic and immunophenotypic findings. A) At present
maturation and no significant increase in blasts or monocytes. The core bio
predominance. Flow cytometry reveals granulocytic predominance (in gree
(in red). B) At follow-up, the morphologic and immunophenotypic findingsmaturation, and occasional atypical granulocytes and
megakaryocytes, but no significant increase in mono-
cytes or myeloblasts (Figure 1). A myeloid neoplasm
positive for CD13 and CD33 was diagnosed, best clas-
sified as MDS, refractory cytopenia with multilineage
dysplasia. Data on therapeutic interventions were not
available for this study. At the 5-month follow-up, the
overall morphologic and immunophenotypic findings
were similar to those at initial presentation.
Chromosome and FISH study
Bone marrow cells were cultivated for 24 and 48 hours
in RPMI 1640 or Marrow Max Medium with 10% fetal calf
serum (Life Technologies, Grand Island, NY 14072, USA).
In total, 20 mitoses were analyzed according to the
ISCN (International System for Human Cytogenetic
Nomenclature), with a resolution of 300 bands per
haploid karyotype. FISH analyses using a panel of MDS
probes (−5/5q-, −7/7q-, +8 and 20q-; Vysis, Downers
Grove, IL, USA) and BlueGnome probes RP11-114B12
(Illumina, San Diego, CA, USA) for the deleted region
5q31.2 were performed on interphase cells according
to the manufacturer’s protocol. Subsequently, 200 cells
were examined carefully.
Oligo SNP array
Microdeletion/microduplication screening was performed
using an SNP-array platform (CytoScan HD SNP array;ation, there was granulocytic predominance with progressive
psy shows hypercellular bone marrow with left-shifted granulocytic
n) but no significant increase in monocytes (in blue) or myeloblasts
are similar to those at presentation.
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instructions. The CytoScan HD array has 2.67 million
probes, including 1.9 million copy number probes and
0.75 million SNP probes. Array data were analyzed
using the Chromosome Analysis Suite (ChAS) software
v 2.0 (Affymetrix).
Mutation analysis
Genomic DNA was also tested for mutations in 19 genes
that are recurrently mutated in myeloid neoplasms,
including ASXL1, EZH2, RUNX1, IDH1, IDH2, KRAS,
NRAS and TET2. Sequencing was performed using a
TruSeq custom amplicon assay on the MiSeq sequencing
platform (Illumina, Hayward, CA). Analysis was performed
using SeqPilot software (JSI Medical Systems, Costa Mesa,
CA). The assay had sufficient read depth to provide a mini-
mum sensitivity of 5% to 10% for mutation detection.Figure 2 Routine cytogenetic and fluorescence insitu hybridization (F
female karyotype. B-D) FISH analyses show normal hybridization with an M
probe D5S23 (5p15.2, green signal) in B; D7S486 (7q31, red signal) and its c
(green signal) for chromosome 8 centromere and D20S108 (20q12, red sigResults and discussion
During the initial evaluation of the patient, cytogenetic
analysis revealed a normal karyotype and FISH studies were
negative for aCNAs commonly seen in MDS (MDS panel)
(Figure 2A-D). Microarray analysis revealed a microdeletion
of approximately 896 kb at the 5q31.2 chromosomal region
and three segments of somatic cnLOH for the entire
long arm of chromosome 4 (136 Mb), the distal half of
the long arm of chromosome 7 (50 Mb), and the entire
chromosome 22 (31 Mb). The microdeletion at 5q31.2
extended from 137,821,899 to 138,718,504 bp (UCSC gen-
ome Browser; http://genome.ucsc.edu/; hg19 release) and
included the ETF1, HSPA9, SNORD63, CTNNA1, LRRTM2,
SIL1, SNHG4, MATR3, SNORA74A, PAIP2, and SLC23A1
genes (Figure 3).
Of the genes deleted due to this microdeletion, two
are tumor suppressor candidate genes associated withISH) results. A) G-banded chromosome analysis shows a normal
DS panel using probes for EGR1 (5q31, red signal) and its control




Figure 3 5q31.2 deletion. A) Chromosome 5 with deletion at q31.2. B) SNP-array results, including the weighted log2 ratio, copy number state,
and allele peaks at the deleted region. C) Database of genomic variants showing an 896-kb deletion in the short arm of chromosome 5 within
band q31.2 (position 137,821,899 to 138,718,504), including the CTNNA1 and HSPA9 genes.
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and HSPA9, which encodes heat-shock 70-KD protein
9 (mortalin) [35]. Deletion of CTNNA1 was confirmed
by applying BlueGnome FISH probes (RP11-114B12)
(Figure 4). Alpha-catenins such as that encoded by
CTNNA1 are essential for the regulation of cell-cell and
cell-matrix interactions in tissues [36]. Loss of expression
of the CTNNA1 tumor suppressor gene in hematopoietic
stem cells may provide a growth advantage that contributes
to human MDS/AML with 5q deletion [37]. Furthermore,
loss of the CTNNA1 expression has been associated with
leukemia progression or transformation of MDS to AML
[38]. The HSPA9 gene is also located at the 5q31.2 regionfrequently deleted in MDS/AML, making it a candidate
tumor suppressor gene; this is consistent with the bio-
logical function of its murine homologue. Human mortalin
(encoded by HSPA9) was originally identified by its close
homology to murine mortalins, which play important
roles in cellular senescence [39]. The HSPA9 gene is a
novel negative regulator of Raf/MEK/ERK pathway that
may be a potential therapeutic target [40].
The combined size of cnLOHs spanning at least 10 Mb
across the genome was approximately 217.6 Mb (Figure 5).
These were detected at the long arm of chromosomes
4, 7, and 22. The cnLOH might result from mitotic re-
combination or nondisjunction which leads to segmental
Figure 4 FISH inverted DAPI image showing deletion of the
CTNNA1 gene using the BlueGnome FISH probe RP11-114B12
(5q31.2, red signal). The deleted chromosome 5 is indicated by an arrow.
Figure 5 SNP-array results at diagnosis showing loss of heterozygosit
bars next to the corresponding chromosomes.
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UPD (cnLOH) at diagnosis in our case is indicative of
neoplastic evolution [12,13]. An additional UPD was identi-
fied at 14q in the follow-up study 5 months later, confirm-
ing the genetic progression of disease (Figure 6).
Recent investigations have indicated that cnLOH can
be responsible for homozygosity of mutations in critical
genes within the region. Reduction to homozygosity as a
consequence of cnLOH was initially thought to be a
mechanism for only inactivation of tumor suppressor
genes [14,41,42]; however, identification of cnLOH in
leukemia has shown that oncogeneic mutations are
also targeted [13,16,17].
Mutation analysis of 19 MDS-associated genes re-
vealed an ASXL1 frameshift/stop mutation (Y591*, 41%
of reads), an EZH2 point mutation (R690H, 85%), two
RUNX1 frameshift/stop mutations (c.474dupT, 19% and
c.424_425ins11bp, 7%), and two TET2 frameshift/stop
mutations (c.1510_1513delAAAA, 77% and R1465*, 10%).
These mutated genes are located on chromosomes 20, 7,
21, and 4, respectively. Recent studies have shown that
TET2 mutations are present in up to 30% of MDS/MPNy (LOH) at the long arm of chromosomes 4, 7, and 22 as purple
Figure 6 SNP-array results at the follow-up study showing loss of heterozygosity (LOH) of chromosome 14, in addition to the LOH
chromosomes 4, 7, and 22 found at initial diagnosis. LOH is shown as purple bar next to the corresponding chromosome.
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commonly reported [43]. The finding of mutations in
all four of these myeloid regulatory genes suggests that
they play a critical role in the pathogenesis of this case and
demonstrate that mutation analysis is useful in cytogeneti-
cally normal myeloid disorders [43].
The cnLOH affecting chromosome 7q and homozygous
EZH2 mutation have been reported in 10% of AML
and MDS cases. They have been associated with a poor
prognosis [9,26,44] and clonal evolution [45,46], supporting
the possible role of EZH2 as a tumor suppressor gene
for myeloid malignancies.
In contrast to the mutated TET2 and EZH2 genes,
no LOH was found for the other two mutated genes
(RUNX1 and ASXL1). RUNX1 mutations have been
proposed as clinically useful biomarkers to follow disease
progression from MDS to AML as well as to monitor
minimal residual disease (MRD) [47]. Moreover, RUNX1
mutations were demonstrated to be frequent in de novo
AML with non-complex karyotypes and conferred anunfavorable prognosis [48] explained by an association
with resistance to chemotherapy [49].
Mutations in ASXL1 have been identified in MDS,
AML, chronic myeloid leukemia, chronic myelomonocytic
leukemia (CMML), and juvenile myelomonocytic leukemia
[50-54], and act as a tumor suppressor in myeloid malig-
nancies [50]. Mutations in ASXL1, TET2, and EZH2 have
been found in 41% of MDS cases in a Chinese population
[44], similar to the data reported in patients of European
decent with MDS [21,23,24,55,56].
Conclusion
In conclusion, our study identified four large cnLOH and
a microdeletion at 5q31 harboring two tumor suppres-
sor genes (CTNNA1 and HSPA9) in an MDS case with
an apparently normal karyotype. The regions of cnLOH at
chromosomes 4, 7, 14, and 22 confirm and extend previous
studies, supporting that cnLOHs in myeloid disorders are
common and nonrandom. Moreover, the presence of an
additional aUPD 14q at follow up, along with persistence of
Hemmat et al. Molecular Cytogenetics 2014, 7:35 Page 7 of 9
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entation, indicates genetic progression of the disease. The
deletion of tumor suppressor genes CTNNA1 and HSPA9,
along with mutation of candidate myeloid regulatory genes
TET2 and EZH2, supports the diagnosis of MDS and likely
portends a poor prognosis.
This study attests to the fact that some patients with a
myelodysplastic syndrome exhibiting a normal karyotype
may have underlying genetic abnormalities detectable
by chromosomal microarray and/or targeted mutation
analyses. Further genomic and molecular studies on a
series of patients with MDS may yield information on
how to stratify this category of disease to seek further
molecular definition.
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